

## FORM 9

### **NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES**

**(or securities convertible or exchangeable into listed securities<sup>1</sup>)**

Name of Listed Issuer:

Symbol(s):

Curaleaf Holdings, Inc. (the "Issuer").	CURA
---	------

Date: January 21, 2020

Is this an updating or amending Notice:            Yes             No

If yes provide date(s) of prior Notices: \_\_\_\_\_.

Issued and Outstanding Securities of Issuer Prior to Issuance: 371,019,675

#### **Pricing**

Date of news release announcing proposed issuance: \_\_\_\_\_ or

Date of confidential request for price protection: \_\_\_\_\_

Closing Market Price on Day Preceding the news release: \_\_\_\_\_ or

Day preceding request for price protection: \_\_\_\_\_

#### **Closing**

Number of securities to be issued: 1,772,062

Issued and outstanding securities following issuance: 372,791,737

#### **Instructions:**

1. For private placements (including debt settlement), complete tables 1A and 1B in Part 1 of this form.
2. Complete Table 1A – Summary for all purchasers, excluding those identified in Item 8.
3. Complete Table 1B – Related Persons only for Related Persons
4. If shares are being issued in connection with an acquisition (either as consideration or to raise funds for a cash acquisition) please proceed to Part 2 of this form.
5. An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10 – Notice of Proposed Transaction
6. Post the completed Form 9 to the CSE website in accordance with *Policy 6 – Distributions*. In addition, the completed form must be delivered to [listings@thecse.com](mailto:listings@thecse.com) with an appendix that includes the information in Table 1B for ALL places.

**Part 1. Private Placement**

**Table 1A – Summary**

Each jurisdiction in which purchasers reside	Number of Purchasers	Price per Security	Total dollar value (CDN\$) raised in the jurisdiction
Total number of purchasers:			
Total dollar value of distribution in all jurisdictions:			

**Table 1B – Related Persons**

Full Name & Municipality of Residence of Placee	Number of Securities Purchased or to be Purchased	Purchase price per Security (CDN\$)	Conversion Price (if Applicable) (CDN\$)	Prospectus Exemption	Total Securities Previously Owned, Controlled or Directed	Payment Date <sup>(1)</sup>	Describe relationship to Issuer <sup>(2)</sup>

<sup>1</sup>An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10.

- Total amount of funds to be raised: \_\_\_\_\_ .
- Provide full details of the use of the proceeds. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material. \_\_\_\_\_ .

3. Provide particulars of any proceeds which are to be paid to Related Persons of the Issuer: \_\_\_\_\_  
\_\_\_\_\_ .
4. If securities are issued in forgiveness of indebtedness, provide details of the debt agreement(s) or and the agreement to exchange the debt for securities.
5. Description of securities to be issued:
- (a) Class \_\_\_\_\_ .
  - (b) Number \_\_\_\_\_ .
  - (c) Price per security \_\_\_\_\_ .
  - (d) Voting rights \_\_\_\_\_ .
6. Provide the following information if warrants, (options) or other convertible securities are to be issued:
- (a) Number \_\_\_\_\_ .
  - (b) Number of securities eligible to be purchased on exercise of warrants (or options) \_\_\_\_\_  
\_\_\_\_\_ .
  - (c) Exercise price \_\_\_\_\_ .
  - (d) Expiry date \_\_\_\_\_ .
7. Provide the following information if debt securities are to be issued:
- (a) Aggregate principal amount \_\_\_\_\_ .
  - (b) Maturity date \_\_\_\_\_ .
  - (c) Interest rate \_\_\_\_\_ .
  - (d) Conversion terms \_\_\_\_\_ .
  - (e) Default provisions \_\_\_\_\_ .
8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the placement (including warrants, options, etc.):

- (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the placement (name, and if a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): \_\_\_\_\_ .
  - (b) Cash \_\_\_\_\_ .
  - (c) Securities \_\_\_\_\_ .
  - (d) Other \_\_\_\_\_ .
  - (e) Expiry date of any options, warrants etc. \_\_\_\_\_ .
  - (f) Exercise price of any options, warrants etc. \_\_\_\_\_ .
9. State whether the sales agent, broker, dealer or other person receiving compensation in connection with the placement is Related Person or has any other relationship with the Issuer and provide details of the relationship \_\_\_\_\_  
\_\_\_\_\_ .
10. Describe any unusual particulars of the transaction (i.e. tax “flow through” shares, etc.).  
\_\_\_\_\_ .
11. State whether the private placement will result in a change of control.  
\_\_\_\_\_ .
12. Where there is a change in the control of the Issuer resulting from the issuance of the private placement shares, indicate the names of the new controlling shareholders. \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_ .
13. Each purchaser has been advised of the applicable securities legislation restricted or seasoning period. All certificates for securities issued which are subject to a hold period bear the appropriate legend restricting their transfer until the expiry of the applicable hold period required by National Instrument 45-102 Resale of Securities.

## Part 2. Acquisition

1. Provide details of the assets to be acquired by the Issuer (including the location of the assets, if applicable). The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material:

Curaleaf Holdings, through its wholly owned subsidiary PalliaTech Florida, Inc. (the “Curaleaf Purchaser”), has completed the acquisition (the “Acquisition”) of a 11.38% interest in PalliaTech Florida, LLC (the “PT FL Units”) from Jayson Weisz (“Weisz”) and JRF Group, LLC (“JRF”, and together with Weisz, the “Selling Parties,” and each a “Selling Party”). The PT FL Units represent a 7.97% indirect interest in Curaleaf Florida, LLC, the Company’s Florida operating business (“Curaleaf FL”). As a result of the Acquisition, the Curaleaf Purchaser has increased its interest in PalliaTech Florida, LLC from 77.24% to 88.62% and its indirect interest in Curaleaf FL from 84.1% to 92.0%.

The Curaleaf Purchaser acquired the PT FL Units from the Selling Parties for consideration consisting of USD\$2,500,000 in cash and the issuance of 1,772,062 Subordinate Voting Shares of the Issuer (the “Consideration Shares”), representing USD\$10,000,000 in consideration based on the agreed-upon price of USD\$5.64 per Consideration Share, or USD\$12,080,501, based on the price of USD\$6.82 per Consideration Share, being the closing trading price as of January 21<sup>st</sup>, 2020.

The Acquisition was completed pursuant to an agreement (the “Agreement”), dated and effective as of January 10, 2020 (the “Effective Date”) made and entered into by and between Selling Parties and Robert Crown, Justin Ort and Midtown General Partners (collectively the “JRF Members”), and Sadis & Goldberg LLP (collectively with the Selling Parties and the JRF Members, the “Weisz-JRF Parties,” and each a “Weisz-JRF Party”), and PalliaTech Florida LLC (“PT FL”), the Curaleaf Purchaser, Curaleaf FL, Curaleaf, Inc. (“Curaleaf”), Boris Jordan (“Jordan”), Joseph Lusardi (“Lusardi”) and Curaleaf Holdings, Inc. (“Issuer”) (collectively the “Curaleaf Parties”, and collectively with the Weisz-JRF Parties, the “Parties”).

Pursuant to the Agreement, in addition to completing the Acquisition, the Parties have settled and released all mutual claims regarding the Sellers Parties’ participation in PalliaTech Florida, LLC and indirect participation on Curaleaf FL, including without limitation claims raised by the Selling Parties in (i) that certain Corrected Third Amended Complaint, dated September 24, 2019, asserting various claims against Curaleaf FL, PT FL Inc., Curaleaf, Lusardi, and Jordan, Case No. 2019-00811-CA-01(44), Circuit Court of the Eleventh Judicial Circuit in and for Miami-Dade County, Florida; and (ii) that certain Second Amended Demand for Arbitration, dated April 17, 2019, asserting various claims against PT FL, PT FL Inc., and Lusardi, Case No. 01-18-004-5355 (American Arbitration Association).

In addition to the statutory holding period of four months and one day, the Consideration Shares will be subject to an additional nine-month lock-up period during which the Selling Parties will not be permitted, collectively, to sell more than 10,000 Consideration Shares per trading day.

2. Provide details of the acquisition including the date, parties to and type of agreement (eg: sale, option, license etc.) and relationship to the Issuer. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the acquisition without reference to any other material: See #1 above.
3. Provide the following information in relation to the total consideration for the acquisition (including details of all cash, securities or other consideration) and any required work commitments:
  - (a) Total aggregate consideration in Canadian dollars: \$20,282,801.10 based on a price per Consideration Share of USD\$7.36 converted into Canadian dollars using an exchange rate of 1.3050.
  - (b) Cash: USD\$2,500,000.
  - (c) Securities (including options, warrants etc.) and dollar value: 1,772,062 Subordinate Voting Shares, representing USD\$10,000,000 in consideration based on the agreed-upon price of USD\$5.64 per Consideration Share used for purposes of the Agreement dated January 10, 2020, or USD\$12,080,501, based on the price of USD\$6.82 per Consideration Share, being the closing trading price as of January 21<sup>st</sup>, 2020.
  - (d) Other: \_\_\_\_\_ .
  - (e) Expiry date of options, warrants, etc. if any: \_\_\_\_\_ .
  - (f) Exercise price of options, warrants, etc. if any: \_\_\_\_\_ .
  - (g) Work commitments: \_\_\_\_\_ .
4. State how the purchase or sale price was determined (e.g. arm's-length negotiation, independent committee of the Board, third party valuation etc).

Arm's-length negotiation
5. Provide details of any appraisal or valuation of the subject of the acquisition known to management of the Issuer: \_\_\_\_\_  
\_\_\_\_\_ .
6. The names of parties receiving securities of the Issuer pursuant to the acquisition and the number of securities to be issued are described as follows:

Name of Party (If not an individual, name all insiders of the Party)	Number and Type of Securities to be Issued	Dollar value per Security (CDN\$)	Conversion price (if applicable)	Prospectus Exemption	Total Securities, Previously Owned, Controlled or Directed by Party	Describe relationship to Issuer <sup>(1)</sup>
Jason Weisz	1,024,268 Subordinate Voting Shares	USD\$6.82 (\$8.90)	N/A	Section 3 of BC Instrument 72-503	None	N/A
Justin Ort	177,207 Subordinate Voting Shares	USD\$6.82 (\$8.90)	N/A	Section 3 of BC Instrument 72-503	None	N/A
Robert Crown	151,688 Subordinate Voting Shares	USD\$6.82 (\$8.90)	N/A	Section 3 of BC Instrument 72-503	None	N/A
Midtown General Partners LLC	25,517 Subordinate Voting Shares	USD\$6.82 (\$8.90)	N/A	Section 3 of BC Instrument 72-503	None	N/A
Sadis & Goldberg LLP	393,382 Subordinate Voting Shares	USD\$6.82 (\$8.90)	N/A	Section 3 of BC Instrument 72-503	None	N/A

(1) Indicate if Related Person

7. Details of the steps taken by the Issuer to ensure that the vendor has good title to the assets being acquired: Not applicable. The PT FL Units were acquired in the context of a settlement.
8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the acquisition (including warrants, options, etc.):
  - (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the acquisition (name, and if a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): \_\_\_\_\_
  - (b) Cash \_\_\_\_\_

- (c) Securities \_\_\_\_\_ .
  - (d) Other \_\_\_\_\_ .
  - (e) Expiry date of any options, warrants etc. \_\_\_\_\_
  - (f) Exercise price of any options, warrants etc. \_\_\_\_\_ .
9. State whether the sales agent, broker or other person receiving compensation in connection with the acquisition is a Related Person or has any other relationship with the Issuer and provide details of the relationship. \_\_\_\_\_  
 \_\_\_\_\_  
 \_\_\_\_\_
10. If applicable, indicate whether the acquisition is the acquisition of an interest in property contiguous to or otherwise related to any other asset acquired in the last 12 months. \_\_\_\_\_  
 \_\_\_\_\_  
 \_\_\_\_\_ .

**Certificate Of Compliance**

The undersigned hereby certifies that:

- 1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance on behalf of the Issuer.
- 2. As of the date hereof there is not material information concerning the Issuer which has not been publicly disclosed.
- 3. the Issuer has obtained the express written consent of each applicable individual to:
  - (a) the disclosure of their information to the Exchange pursuant to this Form or otherwise pursuant to this filing; and
  - (b) the collection, use and disclosure of their information by the Exchange in the manner and for the purposes described in Appendix A or as otherwise identified by the Exchange, from time to time
- 4. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CSE Policy 1).
- 5. All of the information in this Form 9 Notice of Issuance of Securities is true.

*[signature page follows]*



Dated January 21, 2020.

Peter Clateman  
Name of Director or Senior  
Officer

(signed) Peter Clateman  
Signature

Executive Vice President  
Official Capacity

## Appendix A

### PERSONAL INFORMATION COLLECTION POLICY REGARDING FORM 9

The Canadian Securities Exchange and its subsidiaries, affiliates, regulators and agents (collectively, “CSE or the “Exchange”) collect and use the information (which may include personal or other information) which has been provided in Form 9 for the following purposes:

- 
- To determine whether an individual is suitable to be associated with a Listed Issuer;
- To determine whether an issuer is suitable for listing;
- To determine whether allowing an issuer to be listed or allowing an individual to be associated with a Listed Issuer could give rise to investor protection concerns or could bring the Exchange into disrepute;
- To conduct enforcement proceedings;
- To ensure compliance with Exchange Requirements and applicable securities legislation; and
- To fulfil the Exchange’s obligation to regulate its marketplace.

The CSE also collects information, including personal information, from other sources, including but not limited to securities regulatory authorities, law enforcement and self-regulatory authorities, regulation service providers and their subsidiaries, affiliates, regulators and agents. The Exchange may disclose personal information to these entities or otherwise as provided by law and they may use it for their own investigations.

The Exchange may use third parties to process information or provide other administrative services. Any third party will be obliged to adhere to the security and confidentiality provisions set out in this policy.

All personal information provided to or collected by or on behalf of The Exchange and that is retained by The Exchange is kept in a secure environment. Only those employees who need to know the information for the purposes listed above are permitted access to the information or any summary thereof. Employees are instructed to keep the information confidential at all times.

Information about you that is retained by the Exchange and that you have identified as inaccurate or obsolete will be corrected or removed.

If you wish to consult your file or have any questions about this policy or our practices, please write the Chief Privacy Officer, Canadian Securities Exchange, 220 Bay Street – 9th Floor, Toronto, ON, M5J 2W4.